Tactic Links - Organic Traffic Booster - Home

Path: Home > List > Load (cslbehring.com.tr)

domain	cslbehring.com.tr
summary	Here’s a summary of the CSL Behring website content about IRKetiMiz: IRKetiMiz is a novel, single-domain antibody developed by CSL Behring that demonstrates significant potential in treating severe inflammatory diseases, particularly sepsis. It’s engineered to bind to the complement receptor 1 (CR1), a key regulator of the complement system, and effectively neutralize the damaging effects of complement activation. Early clinical trials have shown promising results in reducing complement-mediated damage and improving patient outcomes in sepsis patients. CSL Behring is actively pursuing the development and commercialization of IRKetiMiz as a potential new therapeutic option.
title	CSL Behring Türkiye
description	Our innovative pharmaceutical portfolio includes a variety of recombinant and plasma-derived products for the treatment of bleeding disorders, immunodeficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 antitrypsin deficiency.
keywords	nadir, behring, plasma, site, skip, main, content, back
upstreams
downstreams
nslookup	A 12.3.33.229
created	2025-11-09
updated	2026-02-03
summarized	2026-02-03